MVISX — Patient Opportunity Trust
Data updated: 2026-06-01
MVISX — Patient Opportunity Trust data: holdings, portfolio allocation, expenses, performance, cashflows, risk and SEC filings. United States Multi-Cap / All-Cap Blend / Core Equity · $1.74B AUM · 1.33% expense ratio · 32.6% 1-yr return. From SEC regulatory filings.
MVISX Fund Overview
MVISX — Patient Opportunity Trust is a US mutual fund managed by Advisor Managed Portfolios, categorised as United States Multi-Cap / All-Cap Blend / Core Equity. ABC INVEST provides holdings, performance, costs, cashflows, risk data, prospectus documents and SEC filings, sourced from SEC filings.
- Type: US mutual fund
- Manager: Advisor Managed Portfolios
- Category: United States Multi-Cap / All-Cap Blend / Core Equity
- Assets under management: $1.74B
- 1-year return: 32.6%
- Ticker: MVISX
- SEC CIK: 0001970751
- SEC series ID: S000082973
- Share class ID: C000246410
MVISX Holdings
Top 10 holdings of Patient Opportunity Trust by percentage of net assets, from the fund's latest SEC N-PORT filing.
| Holding | % of net assets |
|---|---|
| Royalty Pharma PLC | 6.91% |
| Citigroup Inc | 6.54% |
| Alphabet Inc | 6.30% |
| QXO Inc | 5.60% |
| Amazon.com Inc | 5.46% |
| NVIDIA Corp | 5.02% |
| UnitedHealth Group Inc | 4.68% |
| Energy Transfer LP | 4.67% |
| IAC Inc | 4.15% |
| Norwegian Cruise Line Holdings | 4.09% |
MVISX Portfolio Allocation
Asset-class allocation of Patient Opportunity Trust by percentage of net assets, from the latest SEC N-PORT filing.
| Asset class | Allocation |
|---|---|
| Equity | 105.7% |
| Derivatives | 3.8% |
MVISX Performance
Total returns for MVISX (as of 2026-08-01), from SEC filings.
| Period | Total return |
|---|---|
| YTD | -5.9% |
| 1 year | 32.6% |
| 3 years (annualised) | 20.6% |
MVISX Risk Information
Risk metrics for MVISX, derived from monthly returns in SEC filings.
- 1-year volatility (annualised): 18.3%
MVISX Costs and Fees
MVISX costs about $133 per $10,000 invested per year in fund expenses.
- Net expense ratio: 1.33%
- Gross expense ratio: 1.33%
- Portfolio turnover: 27%
- Brokerage commissions: 11.58 bps of average net assets (SEC N-CEN)
MVISX Cashflows
Over the 12 months to 2026-03, Patient Opportunity Trust had net outflows of $104.74M, from monthly SEC N-PORT filings.
| Month | Net flow |
|---|---|
| 2026-03 | −$6.74M |
| 2026-02 | −$7.41M |
| 2026-01 | −$4.06M |
| 2025-12 | −$11.70M |
| 2025-11 | −$9.51M |
| 2025-10 | −$16.86M |
MVISX Debt Constituents
No individual debt constituents are reported in Patient Opportunity Trust's latest SEC N-PORT filing.
MVISX Prospectus and SEC Filings
Official Patient Opportunity Trust filings on SEC EDGAR — prospectus, portfolio holdings and annual reports.
Related Funds
Other United States Multi-Cap / All-Cap Blend / Core Equity funds tracked on ABC INVEST:
Data Sources
ABC INVEST compiles this page from public filings made to the U.S. Securities and Exchange Commission (SEC) through EDGAR: portfolio holdings and monthly cashflows from Form N-PORT, expenses and returns from fund prospectuses (Form 485BPOS) and the SEC DERA Risk/Return Summary data sets, annual data from Form N-CEN, and shareholder reports from Form N-CSR.